newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4